Migraine Drugs Market Size, Share | Industry Trends Report, 2020-2025

Posted October 23, 2020 by Globalresearchimarc

Migraine Drugs Market Size, Share | Industry Trends Report, 2020-2025
According to the latest report by IMARC Group, titled “Migraine Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025”, the global migraine drugs market size reached US$ 2.1 Billion in 2019. Migraine drugs refer to medications that are used to reduce the severity of migraines and prevent future attacks. A migraine is a severe, neurological disease with a debilitating headache, characterized by an intense throbbing or pulsing in one area of the head. It is accompanied by sensitivity to light, sound and smell, visual disturbances such as auras, and nausea or vomiting. Migraine drugs do not cure migraines; instead, they treat or relieve these symptoms. There are certain blood pressure medications, as well as some antidepressants, anti-seizure drugs and herbals that are used to reduce the frequency of migraines.

Request Free Sample Report: https://www.imarcgroup.com/migraine-drugs-market/requestsample

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Global Migraine Drugs Market Trends:
According to the Migraine Trust, migraine is the third most common disease globally, with more than 10% of people getting a¬ffected by the condition worldwide. This represents the primary factor that has increased the demand for migraine drugs across the globe. Apart from this, the rising healthcare expenditure and improving reimbursement policies for migraine medications are also acting as growth-inducing factors. Besides this, healthcare providers have made significant advancements in the diagnosis and treatment of migraine. A more advanced treatment modality with mechanism-based therapies, including supraorbital transcutaneous stimulation (STS) and transcranial magnetic stimulation, has been introduced as a preventive therapy for migraine. Additionally, there are many other drugs with novel mechanisms of action or new therapeutic targets, which are in different development stages. Furthermore, for the treatment of the coronavirus disease (COVID-19), market players are testing migraine drugs, which is expected to positively influence the market. For instance, a clinical-stage biopharmaceutical company, Biohaven Pharmaceutical Holding Company Ltd., has been examining Zavegepant to treat acute migraines and has commenced the clinical trial on the same drug to mitigate the neuro-immune consequences among COVID-19 patients. Looking forward, the market is expected to exhibit strong growth during the forecast period (2020-2025).

Market Summary:
• Based on the treatment type, the market has been bifurcated into abortive and preventive treatment.
• On the basis of the drug type, the market has been categorized into triptans, ergot alkaloids, NSAIDs, acetylcholine inhibitors/ neurotoxins, Ditans, CGRP mAbs and others.
• Based on the route of administration, the market has been segmented into oral, injectable and others.
• The market has been classified on the basis of the distribution channel into hospital-based pharmacies, retail pharmacies and others.
• Region-wise, the market has been segmented into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Indonesia, Australia and others), Europe (Germany, France, the United Kingdom, Italy, Russia, Spain and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.
• The competitive landscape of the market has been examined, with some of the key players being Abbott Laboratories, Allergan Plc (AbbVie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies, Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA and Teva Pharmaceutical Industries Limited.

Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/migraine-drugs-market

About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us
30 N Gould St Ste R
Sheridan, WY 82801 USA
Email: [email protected]
Tel No:(D) +91 120 433 0800 |
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
-- END ---
Contact Email [email protected]
Issued By IMARC Group
Business Address IMARC Group 30 N Gould St Ste R Sheridan, WY 82801 USA
IMARC Group 30 N Gould St Ste R Sheridan, WY 82801 USA
Country United States
Categories Health
Tags migraine drugs market
Last Updated October 23, 2020